1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Cardiac metabolic effects of KNa1.2 channel deletion and evidence for its mitochondrial localization

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d110621e238">Controversy surrounds the molecular identity of mitochondrial K <sup>+</sup> channels that are important for protection against cardiac ischemia–reperfusion injury. Although K <sub>Na</sub>1.2 (sodium-activated potassium channel encoded by <i>Kcn2</i>) is necessary for cardioprotection by volatile anesthetics, electrophysiological evidence for a channel of this type in mitochondria is lacking. The endogenous physiological role of a potential mito-K <sub>Na</sub>1.2 channel is also unclear. In this study, single channel patch clamp of 27 independent cardiac mitochondrial inner membrane (mitoplast) preparations from wild-type (WT) mice yielded 6 channels matching the known ion sensitivity, ion selectivity, pharmacology, and conductance properties of K <sub>Na</sub>1.2 (slope conductance, 138 ± 1 pS). However, similar experiments on 40 preparations from <i>Kcnt2</i> <sup>−/−</sup> mice yielded no such channels. The K <sub>Na</sub> opener bithionol uncoupled respiration in WT but not <i>Kcnt2</i> <sup>−/−</sup> cardiomyocytes. Furthermore, when oxidizing only fat as substrate, <i>Kcnt2</i> <sup>−/−</sup> cardiomyocytes and hearts were less responsive to increases in energetic demand. <i>Kcnt2</i> <sup>−/−</sup> mice also had elevated body fat, but no baseline differences in the cardiac metabolome. These data support the existence of a cardiac mitochondrial K <sub>Na</sub>1.2 channel, and a role for cardiac K <sub>Na</sub>1.2 in regulating metabolism under conditions of high energetic demand.—Smith, C. O., Wang, Y. T., Nadtochiy, S. M., Miller, J. H., Jonas, E. A., Dirksen, R. T., Nehrke, K., Brookes, P. S. Cardiac metabolic effects of K <sub>Na</sub>1.2 channel deletion and evidence for its mitochondrial localization. </p>

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion, aging, and heart failure.

          Mitochondria contribute to cardiac dysfunction and myocyte injury via a loss of metabolic capacity and by the production and release of toxic products. This article discusses aspects of mitochondrial structure and metabolism that are pertinent to the role of mitochondria in cardiac disease. Generalized mechanisms of mitochondrial-derived myocyte injury are also discussed, as are the strengths and weaknesses of experimental models used to study the contribution of mitochondria to cardiac injury. Finally, the involvement of mitochondria in the pathogenesis of specific cardiac disease states (ischemia, reperfusion, aging, ischemic preconditioning, and cardiomyopathy) is addressed. Copyright 2001 Academic Press.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

            Nonalcoholic fatty liver disease is strongly associated with hepatic insulin resistance and type 2 diabetes mellitus, but the molecular signals linking hepatic fat accumulation to hepatic insulin resistance are unknown. Three days of high-fat feeding in rats results specifically in hepatic steatosis and hepatic insulin resistance. In this setting, PKCepsilon, but not other isoforms of PKC, is activated. To determine whether PKCepsilon plays a causal role in the pathogenesis of hepatic insulin resistance, we treated rats with an antisense oligonucleotide against PKCepsilon and subjected them to 3 days of high-fat feeding. Knocking down PKCepsilon expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling. Furthermore, we show that PKCepsilon associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro. These data support the hypothesis that PKCepsilon plays a critical role in mediating fat-induced hepatic insulin resistance and represents a novel therapeutic target for type 2 diabetes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mitochondrial channels: ion fluxes and more.

              The field of mitochondrial ion channels has recently seen substantial progress, including the molecular identification of some of the channels. An integrative approach using genetics, electrophysiology, pharmacology, and cell biology to clarify the roles of these channels has thus become possible. It is by now clear that many of these channels are important for energy supply by the mitochondria and have a major impact on the fate of the entire cell as well. The purpose of this review is to provide an up-to-date overview of the electrophysiological properties, molecular identity, and pathophysiological functions of the mitochondrial ion channels studied so far and to highlight possible therapeutic perspectives based on current information.
                Bookmark

                Author and article information

                Journal
                The FASEB Journal
                The FASEB Journal
                FASEB
                0892-6638
                1530-6860
                November 2018
                November 2018
                : 32
                : 11
                : 6135-6149
                Affiliations
                [1 ]Department of Biochemistry, University of Rochester Medical Center, Rochester, New York, USA;
                [2 ]Department of Anesthesiology and Perioperative Medicine, University of Rochester Medical Center, Rochester, New York, USA;
                [3 ]Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA;
                [4 ]Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York, USA;
                [5 ]Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA
                Article
                10.1096/fj.201800139R
                6181635
                29863912
                ed148643-bc9d-4639-824a-533523ba6436
                © 2018
                History

                Comments

                Comment on this article